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by endometrial curetting in 51 patients (52.5%). 94 patients 
underwent surgery (a total abdominal hysterectomy plus bilateral 
salpingo-oopherectomy in 75.5%, simple hysterectomy in 21.6%) with 
lymphadenectomy in only 25 cases. They were classified according to 
FIGO stage on: 61 stage I (12: IA, 7: IB, 42: IC), 13:IIB, 21: III (08 IIIA, 3 
IIIB, 10 IIIC) and 2 IVa. Myometrial invasion was > 50% in 78 % of cases. 
Type I endometrial carcinoma represent the most common type (93 
patients), with histological grade (G); 64% G1, 18.5% G2; 13.5 G3. All 
patients received radiation therapy; (external beam radiotherapy and 
brachytherapy). After median follow up of 49.9 months (2- 120 
months) loco-regional recurrence occurred in 8 patients (8.3%) and 
metastasis in 12 patients (12.3%), the 5-year overall survival rate was 
83 %. There was statistically significant overall survival between stage 
I-II and III-IV p=0.001), however there was no significant overall 
survival between surgery with or without lymphadenectomy (88%, 
87%, p = 0.89), others prognostic factors affecting the overall survival 
were analyzed: comorbidities (without vs. with: 85% vs. 83%), 
hormonal status (pre vs.postmenopausal: 86% vs. 83%), histological 
type (1 vs. 2: 86% vs. 73%), grade (1,2,3) respectively (81%,71%, 40%), 
and the depth of myometrial invasion (<50 vs. > 50%: 94% vs 81%).  
Conclusions: Radiotherapy is a highly effective adjuvant treatment 
providing an excellent loco-regional control rate; pelvic 
lymphadenectomy does not offer clear therapeutic benefit in the 
treatment of endometrial cancer, considering morbidity for 
lymphadenectomy, the technique of sentinel lymph nodes biopsy can 
potentially establish an alternative for staging. Combined therapeutic 
modalities (surgery, radiotherapy, chemotherapy, and targeted 
therapy) can improve survival and prognosis for high-risk endometrial 
cancer. 
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Purpose/Objective: The use of brachytherapy (BT) combined with 
external beam radiotherapy (EBRT), is an essential part of cervical 
cancer radiotherapy treatment and also has an important role in 
developing radiotherapy complications afterwards. During the last 
decade, concepts for three-dimensional image-based treatment 
planning in BT have been developed and that brought closer BT and 
EBRT in terms of technical development. This preliminary study is 
aimed at showing our first clinical results and a dosimetric comparison 
for organs at risk (OAR) using X-ray and CT/MR based BT planning. 
Materials and Methods: Implementation of image–based 
brachytherapy in our Institute was started in November 2008 and till 
June 2009 six patients with advanced cervical cancer were treated 
with this BT planning approach, using PLATO planning system on CT or 
CT/MR fused images. In the beginning of 2012 we started using 
Oncentra as our main planning system and after a transition period, 
results for 2 patients (4 applications) were included. The overall 
treatment approach consisted of pelvic EBRT, concomitant with BT 
and concurrent weekly administration of Cisplatin chemotherapy. All 
patients underwent X-ray 2D based planning, at 3 patients CT, at 3 
patients CT/MR PLATO planning was done at first BT application, and 
for 2 patients (4 applications) MR Oncentra based planning was done 
at first and third BT application, with tandem and two ovoids and TD 
of 7Gy/A. Delineation of rectum, bladder, sigmoid colon and high-risk 
CTV was done according to guidelines by Viswanathan et al and GEC-
ESTRO. The maximum dose to rectum and bladder (Rmax and Bmax), 
based on ICRU recommendation, calculated by X-ray imaging and dose 
to 0,1cm3, 1cm3 and 2cm3, for the bladder, rectum and sigma 
calculated from DVHs were compared. The volume of HR-CTV and 
values of D100, D90 and V100 were also calculated. 
Results: The median dose of EBRT at the time of first BT was 19Gy 
(14-28Gy). HR-CTV mean volume value was 47.54 ± 23.04 cm3 and 
dose parameters D90 6.31± 1.72Gy; D100 3.99 ± 1.43Gy; V100 80.38 ± 
14.48%. Mean dose values for rectum were: Rmax 5,3 ± 2,1Gy, 
D0,1cm3 7,6 ± 2,7Gy, D1cm3 6.0 ± 1,8Gy and D2cm3 5,4 ± 1,5Gy. There 
was statistically significant difference in dose at Rmax and D0,1cm3 
with higher dose obtained at D0,1cm3 and no statistically significant 
difference at the doses of D1cm3 and D2 cm3. Mean dose values for 
bladder were: Bmax 4,4 ± 1,7Gy, D0,1cm3 7.2 ±1.7Gy, D1cm3 5.7 ± 
1.1Gy and D2cm3 55.2 ±1.0Gy and statistically significant higher dose 
was obtained at D0,1cm3 and D1cm3 compared to Bmax. Doses to 
sigmoid colon at D0,1cm3 6.6± 1.9Gy, D1cm3 5.4 ± 1,5Gy and D2cm3 4.9 
± 1,3Gy were found. 
Conclusions: Larger tumor sizes led to inadequate HR-CTV coverage 
with desired BT dose. As expected, mean values of estimated rectum 
and bladder D0.1cm3 volume-dose parameters obtained by 3D BT 
planning, showed higher values compared to those obtained with 2D 
X-ray planning approach. Also, additional information about dose 
values to sigmoid colon was revealed with 3D planning. Further 
investigation in needed in order to fully implement 3D BT in our 
institution and perhaps change our present concomitant EBRT/BT 
treatment approach. 
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Purpose/Objective: To investigate the acute toxicity of 3D conformal 
EBRT with concurrent chemotherapy keeping Dmax around 105% in 
carcinoma cervix patients.  
Materials and Methods: Carcinoma cervix patients stage IIAto IIIB (n = 
22) treated during November 2011 to November 2012 at the institution 
with 3D conformal chemo-radiation were included. They received 
weekly cisplatin 40mg/m2. They received 46 Gy /23 fractions 5 
fractions per week while ensuring that the PTV maximum dose (Dmax) 
is around 105%. EBRT was followed by two fractions of intracavitary 
brachytherapy 9 Gy each. Normally the prescribed dose is normalized 
to the isodose curve that covers at least 99% of PTV which usually 
results in a higher PTV Dmax. (around 110%).In this study the coverage 
of 99% of PTV by the prescribed dose is ensured while maintaining the 
PTV Dmax around 105% and thus better dose homogeneity. This is 
achieved by optimization methods like using subfields, adjusting 
weightages,using mixed beam energies etc. The purpose of the study 
is to analyze how this reflects on the acute RTOG toxicity profile of 
the patient during EBRT. This is a type of dose optimization where an 
IMRT like plan can be generated using conventional 3D CRT despite 
the process being time consuming as the results are expected to be 
better than a conventional 3D CRT plan.  
Results:  
All the 22 patients completed EBRT. The analysis is given below: 
· Age: between 30-55 years (median 45) 
· Stageof disease - IIB (72.72%) and IIIB (27.27%) 
· Numberof cycles of chemotherapy received – 5 cycles (63.63%), 4 
cycles (27.27%) and 3cycles (9.09%). 
· Tumorsize: <4cm (18.18%) and >4cm (81.81%) 
· Performance status: ECOG 1 (77.27%) and ECOG 2 (22.72%) 
· TOXICITY ASSESSMENT: ( RTOG gradewise in percentages ) 
 
Toxicity in % Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Skin 50 40.9 9.09 0 0 
Vaginal Mucosa 81.81 18.18 0 0 0 
Rectum 50 36.36 13.63 0 0 
Diarrhoea 45.45 81.2 13.63 9.09 0  
Vomitting 63.63 13.63 13.63 9.09 0 
Small bowel 35.29 35.29 11.76 17.6 0 
Large Bowel 47.05 41.17 11.76 0 0 
Neutropenia 72.72 22.72 0 4.5 0 
Anemia 9545 0 0 454 0 
Thrompcytopenia 90.9 4.5 4.54 0 0 
 
Conclusions: The predominant toxicity was small bowel toxicity 
followed by hematological toxicity. 3D conformal concurrent chemo 
radiation with Dmax around 105% reduces acute RTOG toxicity 
particularly grade 3 and 4, results in better dose homogeneity and 
improves patient compliance for radiotherapy.  
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Purpose/Objective: To report the experience with FDG PET/CT 
guided-Tomotherapy and simultaneous integrated boost dose 
escalation (SIB) as a substitute for brachytherapy or to increase the 
dose to the FDG PET positive lymph nodes. 
Materials and Methods: From 08/2006 -05/2012 40 gynecologic cancer 
pts received pelvic/pelvic-lombo-aortic FDG PET/CT Guided 
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Tomotherapy treatments. Median age of these patients was 60.6 yrs 
(21.6- 88.5). Median follow up was 15.7 mts (0.4- 58). They were 20 
cervical, 10 endometrial, 4 vaginal, 1 vulvar and 5 ovarian cancer. 
Four pts presented stage I, 9 stage II, 8 stage III, 2 stage IV,1 NA and 
16 relapsing tumors. Fourteen patients had a previous surgery. 
PET/CTsimulation was always performed to include pelvic or lombo- 
aortic N+ and tumor localizations in SIB. Fifteen patients were treated 
without SIB, with doses ranging from 45Gy/ 20 fr to 65.4 Gy/ 33 fr. 
Twenty five patients, who could not undergo BT or who had positive 
lymph nodes at FDG PET/CT, were treated with 45-50.4 Gy to 
pelvic/lombo-aortic lymph-nodes and a SIB on PET positive lymph-
nodes or central tumor. The median dose prescribed was 60 Gy( 45- 
66.25) in a median number of 28 fr (6- 33). Some of the cervical 
cancer patients also received concomitant chemotherapy. 
Results: RTOG acute toxicity was asf ollows: GE( diarrhea, nausea, 
vomiting) : G1= 9, G2= 14, G3= 1; GI(bleeding,tenesmus): G1= 1, G2= 
2; GU: G1= 7, G2= 6; hematologic (neutropenia): G1= 1,G2=1; G3= 1; 
dermatitis: G1= 3, G2=9, asthenia G1= 3. RTOG/EORTC late toxicity 
was: GE: G1= 3, G2= 1; GI: G3=1; GU: G1=2, G2=2; radiation 
dermatitis: G1=1.One patient presented vaginal sthenosis after 
exclusive HT treatment to 66,25Gy. Twenty CR, 9 PR, 2 SD and 2 PD 
were registered. Seven patients presented distant progressive disease 
with local CR (5)or PR (2) at the first evaluation. The 2 SD and 2 of PR 
presented local PD atthe next follow up. Thirteen patients have 
chosen to continue the follow up only with the gynecologist. Six 
deaths were registered among the patients who continued follow up, 
five in patients with PD, one in a patient with local CR but with brain 
metastases. 
Conclusions: The toxicity and local control results were good in this 
group of patients, demonstrating that, when necessary, brachytherapy 
could be replaced, and PET positive lymph nodes controlled, with the 
SIB technique. Disease progression with distant (lung,peritoneum) 
metastasis is indicative that a better systemic therapy should be 
developed.  
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Purpose/Objective: Cervical cancer is still on the five place of 
cancers in woman on the world. Radiotherapy, alongside with surgery 
and chemotherapy, is an important part of the therapeutic process in 
women suffering from these cancers. In the advance cases 
combination of radio and chemotherapy start to be the gold standard 
of treatment. The aim of this study was to assess the therapeutic 
effect according to five years survival and analysis of association 
between prognostic factors and results of the treatment. 
Materials and Methods: The study covered 151 patients with 
diagnosed FIGO stage IIB and IIIB cancer of the cervix treated on 2002 
to 2005 year. All patients received external-beam radiation therapy 
(EBRT) and brachytherapy (BRT) in combination with chemotherapy 
(CHT)– Cisplatin at 40mg/m² administered once a week over the 
radiotherapy period. The mean age of patients was 51 years old. 
91,6% got planoepitheliale carcinoma histopathology. The mean tumor 
size was 4,96cm, bigger in the group with IIIB cancer- 5,23cm. An 
average to point A dose in this group of patients was 87,1 Gy; 31,9Gy 
by the teleradiotherapy and 52,2Gy by the brachytherapy LDR or PDR. 
Chemotherapy was given in 1-7 curses, with mean dose of 4,7 curses, 
69,5% of patient got 5 and more courses. Meantime of the treatment 
was 38 days. The radiochemotherapy results were evaluated based on 
medical documentation and irradiation sheets. Subject to 
investigation was time of survival, present of absent of disease or 
metastasis and both early and late toxicity observed during a five year 
follow-up. 
Results: After five year observation we found that 88 patients (58,3%) 
was still alive and 63 patients (41,7%) died during this observation. 
Mean time to dead in group of 63 patient was 25,2 months after 
treatment. In 35 cases of death patients and in 13 cases with 5 years 
survival metastasis or recurrence was observed. Most important 
factors to five years survival was tumor volume (p<0,05) and 
associated with it stage of the disease. In the group with IIB stage 75% 
survived 5 years, in IIIB 53,8%. Rest of factor was important in 
comparing of IIB and IIIB stages, like dose of tele and brachytherapy, 
number of chemotherapy courses and prolong time of treatment. 
Conclusions: Radiochemotherapy became the gold standard in 
advanced cervical cancer women. During classification to that kind of 
treatment we must however remember that many factors became this 
treatment effectiveness or not. In some cases individualization of 
radio and chemotherapy combination can profiter with higher percent 
of five years survival.  
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Purpose/Objective: Hypofractionated treatment with intensity 
modulated radiotherapy (IMRT), arc therapy, stereotactic body 
radiotherapy (SBRT) and Cyberknife is a valid conservative alternative 
in exclusive or recurrent gynaecological cancer when brachytherapy is 
not feasible . 
Materials and Methods: In our 'Advanced Radiotherapy Center' the 
majority of patients (pts) affected by gynaecological cancer were 
treated with conventional or hypofractionated radiotherapy 
±brachytherapy boost. From June 2010 to October 2012 186 
gynaecological pts (90 exclusive cervical cancer) were treated. When 
brachytherapy is inadequate or not feasible, hypofractionated 
schedule with external beams is a very good solution (virtual 
brachytherapy). The introduction of new technologies such as IMRT, 
Rapid-arc therapy, SBRT, Cyberknife and the application of image 
guidance and adaptive planning techniques makes easier to spare 
critical organs at risk (OAR) in order to minimize late toxicity, that is 
a concern because of the closeness among OAR and target. In order to 
compare the different fractionation schedules, 2 Gy equivalent total 
doses (EQD2) were calculated using the linear quadratic model with 
α/β ratios of 3 Gy for late normal tissue effects and 10 Gy for the 
tumor. 
Results: All patients but five received Rapid arc radiotherapy with 
simultaneous integrated boost (SIB) :45-50.4 Gy (1.8 Gy/fraction (fr)) 
were prescribed to the T or T- bed, N0 pelvic and/or para-aortic 
lymph nodes and 55 Gy (2.2 Gy/fraction) to the positive lymph 
nodes.The dose for the hypofractionated boost schedule was 5 Gy/fr 
for 3 fr = 15 Gy , EQD2=18.8 Gy (PTV 65% ) isocenter EQD2=83 Gy or 5 
Gy/fr x 5 fr : 20 Gy EQD2 = 25 Gy.For the pts who received the 
hypofractionated treatment alone the doses for IMRT or SBRT was: 6 
Gy /fr x 5 fr= 30 Gy (isodose 95%)= EQD2=40 Gy, 5 Gy /fr x 5 fr = 25 Gy 
(isodose 95%) EQD2=30 Gy. 
Conclusions: The possibility to hypofractionate the treatment offers a 
new approach for a minimally invasive treatment in the management 
of cancer when current surgical approach and other conventional 
radiotherapy techniques are unsuitable. 
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Purpose/Objective: To assess the outcome and quality of life of 
patients of carcinoma cervix treated with multimodality therapy using 
the LENT SOMA scores. 
Materials and Methods: Patients:The study was prospective and 
patients who were treated in CMC, Ludhiana between 1st January 
1995to 31st December 2007 and coming for follow up were included in 
this study after ethical clearance. A total of 85 patients were accrued 
comprising 6 stage IB, 6 stage II A, 25 stage II B, 2 stage IIIA, 45 stage 
III B and 1 stage IV A disease. Sixty six patients were treated with 
radiotherapy in which 45 patients received chemotherapy with 
radiotherapy and 19 had surgery prior to post-operative radiotherapy. 
The mean age was 47.81 years with a range of 25–68 years. 
Radiotherapy was given according to the Manchester school.  
Completion of LENT SOMA scale vagina sub-section (including sexual 
dysfunction) was done and Statistical analysis was done. 
Results:  
Completion of questionnaires: From a consecutive series of 92 
patients, 7 patients data were not adequate. Three patients were 
reported to have recurrence either local or metastatic. Initial data 
were obtained for 85 women. 
 Treatment data: Pre-radiotherapy LENT subjective scores for the 
vagina and sexual dysfunction scales were not obtained.  
There was a significant relationship between the average baseline 
scores and patient age (P =0:037) for the vagina scale score and also 
for sexual dysfunction (P =0:038). There was a significant relationship 
between the maximum vagina scores at baseline and age (P =0:039), 
but not for stage of disease (P = 0:077). For sexual dysfunction 
maximum scores there was no significant association with age (P 
